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Essential medicines and 
access to insulin
We fully support the views expressed 
in The Lancet Diabetes & Endocrinology’s 
Editorial1 about ensuring affordable 
access to insulin and the proposal 
to add analogue insulin to the 
WHO Essential Medicines list. The 
International Insulin Foundation in 
its 2011 position statement called 
for “the universal access for persons 
with type 1 diabetes to life-saving and 
life-preserving insulin”.2 In 2012, we 
launched the 100 Campaign, which 
sets the target of 100% affordability 
and 100% availability of insulin 
worldwide by the year 2022 (100 years 
after the introduction of insulin for 
people with diabetes). With our focus 
on improving access to insulin, we 
were very surprised by the proposal to 
include analogue insulins on the WHO 
Model List of Essential Medicines.
Problems with the price and 
affordability of insulin are not confined 
to low-income and middle-income 
countries: the price of insulin in the 
USA has been attracting attention.3 
The main driver of this issue is that 
analogue insulins are much more 
expensive than human preparations 
and their use is becoming more 
prominent worldwide. The price excess 
varies between countries, but recent 
(2016) multi-country data from the 
ACCISS study4 show that glargine and 
detemir insulins are seven to nine times 
more expensive than human insulins. 
Besides cost, we are concerned that, 
although the current use of analogue 
insulins is directed towards people 
with type 1 diabetes, market forces will 
probably encourage use of analogue 
insulins by people with type 2 diabetes, 
leading to an increased economic 
burden for countries and individuals. 
The evidence base for the superiority 
of analogue insulins is also weak. 
The application to WHO is supported 
by a systematic review and network 
meta-analysis5 that largely comprised 
open-label, manufacturer-sponsored 
studies. As a result, in the submission’s 
summary tables, all but two studies 
are described as at serious or very 
serious risk of bias. Many of the studies 
compared long-acting analogues 
with once daily isophane insulin. 
The systematic review described the 
benefits of analogues as “probably 
superior” to isophane insulin with 
respect to HbA1c, with the authors 
noting that the “difference is small” 
and “no differences are likely to 
be clinically relevant”; for cost-
effectiveness, the results “were 
inconsistent across studies”.5
We therefore agree with the 
conclusions of the Editorial that access 
to human insulin is still “despairingly 
low” for many patients worldwide and 
that adding more expensive insulins 
to the WHO model list is not likely to 
improve this situation.1 We trust that 
WHO will reject this application.
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